Fast-acting allergy relief for dogs – Apoquel starts working in 4 hours

Your dog’s itching, scratching and rubbing could be caused by allergic skin disease, atopic dermatitis. Apoquel works by reducing the itch signals your dog's immune system sends, calming the sensation of itch and the urge to scratch – helping to improve your dog’s quality of life.

Use Left and Right Arrow keys to navigate between slides.

Clock icon
Starts to relieve itch within 4 hours1
Effectively controls itch within 24 hours2
Reduces redness and irritation of your dog’s skin3
Easy to give, with or without food4
Can be used alongside other common therapies

Why use Apoquel?

10+
Years proven safety record
No.1
Apoquel is No.1 prescribed oral medicine for allergic itch4
16m
Apoquel has been prescribed to over 16 million dogs4

FAQ

Apoquel (oclacitinib) is a prescription tablet for controlling allergic itch and inflammation in dogs
It targets the itch and inflammation signals in a dog’s immune system, helping to break the cycle of scratching and discomfort
Prescribed for allergic skin conditions, such as atopic dermatitis and allergic dermatitis
Many dogs feel relief within 4 hours, with full itch control in 24 hours
Yes, Apoquel can be given with most other treatments, including vaccines, under veterinary guidance
Yes, with a prescription from your veterinary professional
References

1. Gadeyne C et al. Efficacy of oclacitinib (APOQUEL®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014; 25: 512–e86.

2. Gadeyne C et al. Efficacy of oclacitinib (APOQUEL®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014; 25: 512–e86.

3. Cosgrove SB et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (APOQUEL®) in client-owned dogs with atopic dermatitis. Vet Dermatol 2013; 24: 587−e142.

4. APOQUEL® SPC.